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Abstract
Background: Airway fibrosis is one of the pathological features of chronic obstructive pulmonary disease (COPD),
and recent studies revealed that acetylcholine plays an important role in the development of airway remodeling by
stimulating proliferation and collagen synthesis of lung fibroblasts. This study was designed to examine the effects
of a long-acting muscarinic receptor antagonist (LAMA) glycopyrronium and a long-acting β2 adrenergic receptor
agonist (LABA) indacaterol on acetylcholine-mediated fibrotic responses in lung fibroblasts.
Methods: After carbachol (CCh) or transforming growth factor-β1 (TGF-β1) exposure, the response to glycopyrronium
and indacaterol was determined in vitro in fibroblasts isolated from mild-to-moderate COPD lung tissue. The ability of
fibroblasts to mediate the contraction of collagen gels was assessed. The expression of α-smooth muscle actin (α-SMA)
and the phosphorylation of extracellular-signal-regulated kinase 5 (ERK5) were determined by immunoblot. TGF-β1 was
quantified by ELISA and acetylcholine was quantified by liquid chromatography tandem-mass spectrometry.
Results: CCh stimulated fibroblast-mediated collagen gel contraction and α-SMA expression and TGF-β1 release by
fibroblasts. Blockade of autocrine TGF-β1 attenuated CCh-mediated fibrotic responses, while TGF-β1 did not stimulate
acetylcholine release. Glycopyrronium plus indacaterol significantly attenuated CCh- and TGF-β1-mediated fibrotic
responses through inhibition of ERK5 phosphorylation. Notably, the magnitudes of CCh- and TGF-β1-stimulated gel
contraction, CCh-induced TGF-β1 release, and ERK5 phosphorylation were greater in fibroblasts isolated from COPD
subjects than in those from non-smokers.
Conclusions: CCh induced TGF-β1 self-sustaining signaling loops by potentiating ERK5 signaling and promoted
myofibroblast activity. This autocrine signaling mechanism may be an attractive therapeutic target to block the fibrotic
response, which was modulated by the combination of glycopyrronium and indacaterol.
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Background
Persistent long-term airway inflammation contributes to
airway remodeling and permanent alterations of the airway
wall structure. Airway remodeling, including fibrosis, arises
during the early stages of asthma and chronic obstructive
pulmonary disease (COPD), and small airway fibrosis in
COPD is associated with a greater decline in forced expira-
tory volume in 1 s (FEV1) than emphysema [1–3].
Resident lung fibroblasts are activated under chronic
airway inflammation and differentiated into myofibroblasts,
accompanied by an increased expression of α-smooth
muscle actin (α-SMA) and augmented a persistence of
contractile activity (3), contributing to irreversible airflow
limitation [4]. Transforming growth factor (TGF)-β is a
well-known fibrogenic mediator involved in COPD [5, 6],
but recent evidence indicates the potential role of non-
neuronal acetylcholine as a paracrine/autocrine mediator
in the regulation of airway fibrosis [7]. A clinical study
also showed that methacholine inhalations induced
sub-epithelial collagen deposition and TGF-β immuno-
reactivity within the airway epithelium, which are sup-
pressed by a short acting β2-agonist [8].
Acetylcholine is classically known as a neurotransmitter
involved in airway muscle contraction and mucus secre-
tion via the activation of muscarinic receptors, and the in-
creased cholinergic tone of smooth muscle is a major
therapeutic target of airflow limitation in COPD [9]. Not-
ably, acetylcholine may not only be released from para-
sympathetic nerve, but also from airway epithelial cells
and inflammatory cells [10, 11], and cholinergic stimuli in-
crease the proliferation and collagen synthesis of human
lung fibroblasts via extracellular signal-regulated kinase
1/2 (ERK1/2) [12–14] and enhance α-SMA expression
and TGF-β1 production through ERK1/2 and Rho kin-
ase [15]. Furthermore, fibroblasts express choline-ace-
tyltransferase (ChAT), an enzyme regulating acetylcholine
synthesis, and TGF-β1 stimulates ChAT expression
[15, 16]. However, the acetylcholine release from fibro-
blasts has not yet been directly demonstrated. Addition-
ally, extracellular-signal-regulated kinase 5 (ERK5), a
member of the mitogen-activated protein kinase (MAPK)
family, has recently garnered the attention as the positive
regulator of TGF-β signaling, and inhibition of ERK5
ameliorated bleomycin-induced pulmonary fibrosis in
mice [17], but the roles of ERK5 in airway fibrosis remain
unknown.
Long-acting muscarinic antagonists (LAMAs) and
long-acting β2 adrenergic receptor agonists (LABAs) are
widely used as bronchodilators for maintenance therapy
in COPD and asthma [18, 19]. QVA149, a fixed-dose
combination of the LAMA, glycopyrronium (GLY), and
the LABA, indacaterol (IND), is a novel, once-daily dual
bronchodilator that demonstrated rapid and sustained
bronchodilation in patients with moderate-to-severe
COPD [20]. However, whether the combination of LAMA
and LABA modifies airway fibrosis remains unclear,
particularly during early/mild COPD.
In this study, we investigated the effect of GLY and IND
in regulating carbachol (CCh) and TGF-β1-induced ERK5
activation during the fibrotic processes in lung fibroblasts
isolated from patients with COPD. In addition, we ex-
plored a possible link between CCh and TGF-β1 signaling.
Methods
Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) was pur-
chased from Wako (Osaka, Japan) and FCS from
Sigma-Aldrich (St. Louis, MO, USA). Novartis Pharma
AG (Basel, Switzerland) provided GLY and IND. CCh
was from Sigma-Aldrich and TGF-β1 from R&D Systems
(Minneapolis, MN, USA). ERK5 inhibitor, BIX02189, and
activin receptor–like kinase 5 (ALK5) inhibitor, SB431542,
were from Selleckchem (Houston, TX, USA) and ERK1/2
inhibitor, PD98059, from Calbiochem (La Jolla, CA, USA).
Rho-associated coiled-coil forming kinase/Rho binding
kinase inhibitor, Y-27632, was from Wako. The primary
antibodies were anti-ERK5 (Cell Signaling Technology,
Danvers, MA, USA: Catalogue no. #3372), anti–α-smooth
muscle actin (α-SMA) (Sigma-Aldrich: Catalogue no.
A2547), and anti- ChAT antibody (Merck KGaA,
Darmstadt, Germany: Catalogue no. AB144P).
Isolation and primary culture of lung fibroblasts
Human primary lung parenchymal fibroblasts from patients
undergoing lung resection for localized tumor were cul-
tured as described previously [21]. Briefly, the portion of
lung parenchymal tissue that was as distal from any tumors
as possible and free of the pleural surface was minced and
cultured in DMEM supplemented with 10% FCS, 100 μg/
ml penicillin, 250 μg/ml streptomycin, and 1 μg/ml ampho-
tericin B in a humidified atmosphere of 5% CO2. Cells were
assessed in passage 2 after primary culture and displayed
the typical fibroblast morphology and were positive for
vimentin and negative for cytokeratin staining. Lung fi-
broblasts from 22 patients: 11 non-smokers without
clinical airway symptom or lung functional abnormal-
ities, 11 smokers with mild-to-moderate COPD according
to the Global Initiative for Chronic Obstructive Lung
Disease classification (GOLD 1 and 2) were obtained.
Patients with a history of asthma and marked eosinophil
infiltration in airways of resected lungs were excluded.
The Institutional Review Board at the Juntendo University
School of Medicine approved the procedures. All patients
provided written, informed consent (No. 2013051).
Cell culture
Human fetal lung fibroblasts (HFL1; catalogue number
CCL-153) and A549 (catalogue number CCL-185) were
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purchased from the American Type Culture Collection
(Manassas, VA, USA). Lung fibroblasts and A549 cells
were cultured in DMEM supplemented with 10% FCS,
100 μg/ml penicillin, 250 μg/ml streptomycin, and 1 μg/ml
amphotericin B in a humidified atmosphere of 5% CO2.
Sub-confluent cells were removed from the dishes by
0.05% trypsin-EDTA (Wako, Osaka, Japan). For three-
dimensional collagen gel contraction and ELISA, primary
lung fibroblasts were used at the fourth to sixth passages
after isolation to exclude the effect of differences in passage
number and culturing conditions.
Type I collagen preparation
Type I collagen (rat tail tendon collagen, RTTC) was ex-
tracted from rat tail tendons as previously described [22].
Three-dimensional collagen gel contraction assay
The effect of CCh and TGF-β1 on fibroblast-mediated
collagen gel contraction was assessed in the presence/
absence of GLY and IND, BIX02189, and SB431542,
using a modification of a previously described method
[23]. Briefly, sub-confluent fibroblasts were deprived of
serum for 24 h, detached with 0.05% trypsin-EDTA, and
resuspended in serum free DMEM (SF-DMEM). The
cell number was then counted with a Coulter Counter
(Beckman Coulter, Inc., Fullerton, CA, USA). Collagen
gels were prepared by mixing the appropriate amount of
RTTC, distilled water, 4× concentrated DMEM, and cell
suspension. The final mixture was 0.75 mg/ml of colla-
gen, 3 × 105 fibroblasts/ml gel, and a physiologic ionic
strength of 1× DMEM, and a pH of 7.4. A portion of the
gel solution (500 μl) was then casted into each well of a
24-well tissue culture plate with a 1.9 cm2 growth area
(Corning, Costar, NY, USA). Gelation occurred in 20 min
at room temperature, after which the gels were released
from the surface of the culture well using a sterile spatula.
They were then transferred into 60 mm tissue culture
dishes (three gels in each dish) containing 5 ml of SF-
DMEM with or without designated reagents and incu-
bated at 37 °C, 5% CO2 for 3 days. The ability of fibro-
blasts to contract the floating gels was determined by
quantifying the area of the gels daily using an LAS4000
image analyzer (GE Healthcare Bio-Science AB, Uppsala,
Sweden). Data are expressed as the percentage of gel area
compared with the original gel size. Contraction is then
expressed as a decrease in gel area.
Measurement of TGF-β1 release
TGF-β1 release in the monolayer culture media was
measured by ELISA. Sub-confluent lung fibroblasts on a
6-well plate were deprived of serum for 24 h and stimu-
lated with CCh in the presence or absence of GLY or/
and IND. Supernatants were harvested after 24 h, frozen,
and stored at − 80 °C until assay. TGF-β1 production
from lung fibroblasts was determined by human TGF-β1
Immunoassay (R&D Systems; Minneapolis, MN, USA)
according to the manufacturer’s instructions.
Determination of acetylcholine by LC–MS/MS
Acetylcholine (ACh) in the culture supernatants was an-
alyzed by liquid chromatography tandem-mass spec-
trometry (LC-MS/MS). Sub-confluent lung fibroblasts
on a 6-well plate were deprived of serum for 24 h and
stimulated with TGF-β1. After 24 h, supernatants were
transferred to 1.5 ml tubes in the presence of 1 μM riv-
astigmine (Sigma-Aldrich) to prevent ACh degradation.
For ACh measurement, 5 μl of the aliquots were injected
directly into the LC-MS/MS system. LC-MS/MS analysis
were performed on Gilson HPLC system (Gilson, Villiers-
le-Bel, France) connected to TSQ Quantum Ultra AM
mass spectrometer (Thermo Fisher Scientific). ACh was
analyzed in the positive mode and selected reaction moni-
toring (SRM) analysis was carried out. MS conditions were
as follows: The collision energy was 15 eV and the Argon
gas as collision gas was set at 1mTorr. The spray voltage
was 3.5 kV; the capillary temperature was set at 300 °C.
The nitrogen flow rate was 25 units for sheath gas and 5
units for auxiliary gas. Discovery HS F5-3 2.1 mm i.d ×
150 mm, 3 μm column (Supelco, Bellefonte, PA, USA) was
used for LC separation. The column temperature was set
at 40 °C. The mobile phase A consisted of 0.1% formic acid
in water and the mobile phase B consisted of 0.1% formic
acid in 80% acetonitrile (v/v). The elution program started
at 0% B and increased to 40% for 20 min. The flow rate
was set to 0.2 ml/min. To obtain the internal standard re-
port, acetylcholine (Wako, Osaka, Japan) was added to the
SF-DMEM as control.
Immunoblotting
The expression of α-SMA and ChAT as well as ERK5
phosphorylation were evaluated by immunoblotting
analysis of cell lysates by using anti-α-SMA antibody (1:
5000), anti-ChAT antibody (1: 1000), and anti-ERK5
antibody (1: 1000). ERK5 phosphorylation can be detected
by the presence of a band with a slower electrophoretic
mobility shift [24]. Lung fibroblasts were seeded on
60 mm dish at a density of 5 × 104/ml and cultured for
24 h. The medium was then changed to SF-DMEM for
24 h, following which cells were stimulated with CCh and
TGF-β1 in the presence or absence of inhibitors for 48 h.
After treatment, the cells were washed with ice-cold PBS
and lysed with radioimmunoprecipitation assay lysis buffer
(Wako, Osaka, Japan) supplemented with protease in-
hibitor (Thermo Fisher Scientific) and phosphatase in-
hibitor cocktail (Thermo Fisher Scientific). The lysates
were briefly sonicated and then centrifuged at 12,000 rpm
for 10 min. The protein concentration in the supernatants
was measured by BCA Protein Assay Kit (Thermo Fisher
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Scientific). Lysates were solubilized in 4× Laemmli Sample
Buffer (Bio-RAD). Equal amounts of protein were loaded
into each lane, separated in 7.5–10% SDS-PAGE and
transferred to polyvinylidene difluoride membrane. Mem-
branes were blocked for 1 h or overnight in blocking re-
agent. The membrane was probed with antibodies to
ERK5, ChAT, α-SMA, and β-actin. Bound antibodies were
visualized using peroxidase-conjugated second antibodies
and enhanced chemiluminescence with LAS4000 image
analyzer (GE, Healthcare Bio-Science AB) and lumines-
cent images were analyzed with an ImageQuant TL (GE
Healthcare Bio-Science AB).
Statistical analysis
Results are expressed as the means ± SEM. Grouped data
were evaluated by one-way analysis of variance (ANOVA),
corrected by the Bonferroni’s test. Samples that appeared
different within a series were further assessed by Student’s
t-test. Comparisons between non-smokers and patients
with COPD were performed using the unpaired, two-
tailed Mann–Whitney test. For evaluation of experimental
studies within a group where paired samples were avail-
able, the Wilcoxon test was used. For these comparisons,
each subject was considered as an individual point. P
values less than 0.05 were considered significant. All data
were analyzed using GraphPad Prism 6 (GraphPad
Software, San Diego, CA, USA).
Results
Clinical and demographic features
The clinical and demographic features of the patients
are shown in Table 1. The two groups were similar in age
and sex. Patients with COPD were classified according to
the GOLD consensus report criteria as GOLD 1 (n = 3) or
GOLD 2 (n = 8). The lung function differed significantly
between the two groups. As expected, patients with
COPD had lower FEV1/FVC and FEV1% predicted value.
Effect of GLY and/or IND on CCh or TGF-β1-induced collagen
gel contraction and α-SMA expression
To investigate the effect of acetylcholine on tissue fibrotic
response, fibroblast-mediated collagen gel contraction assay
was used as an in vitro model of tissue remodeling. α-SMA
expression was determined as one of contractile stress fi-
bers, leading to gel contraction. Acetylcholine is easily me-
tabolized by acetylcholinesterase. Therefore, we selected
CCh as the long acting cholinergic agonist to stimulate
muscarinic receptors. The expression of muscarinic recep-
tor (M1-3) and β2 adrenergic receptor in HFL1 cells were
confirmed using western blot analysis (data not shown).
CCh significantly augmented HFL1-mediated collagen
gel contraction and α-SMA expression in a time and
concentration-dependent manner (P < 0.05 at 10−6 M,
Fig. 1a-d). CCh were widely used as the concentration
of 10−5M in laboratory setting, but previous study re-
ported human normal bronchi contained 2–3 nmol/g
of acetylcholine [25], suggesting the possibility of lower
concentration than 10−5M acetylcholine. Therefore, we
decided to select 10−6 M CCh in our experiments.
We examined the effect of GLY or IND on HFL1-
mediated collagen gel contraction. IND inhibited gel
contraction in a dose-dependent manner (P < 0.05 at
concentrations of 10−8 to 10−6 M IND compared to control,
Fig. 1f). However, GLY had no inhibitory effect (Fig. 1e).
GLY or IND inhibited CCh-augmented gel contraction in a
dose-dependent manner (P < 0.05 at concentrations of 10−8
to 10−6 M GLY and of 10−9 to 10−6 M IND compared with
control, Fig. 2a and b). IND inhibited gel contraction in the
presence of TGF-β1, which is known as a key mediator in
the development of fibrosis and strongly stimulates collagen
gel contraction and α-SMA expression in fibroblasts
[26, 27] (P < 0.05 at concentrations of 10−9 to 10−6 M
IND compared to TGF-β1 alone, Fig. 2d). Nevertheless,
GLY had no effect on TGF-β1-mediated gel contraction
(Fig 2c). In clinical settings, the maximum
Table 1 Clinical and demographic features of patients
No. of Non-smokers Patients Mean ± SD No. of Patients with COPD Mean ± SD
Age, y 11 64 ± 8 11 66 ± 9
Sex, no. male/female 5/6 8/3
Smoking status
Never smoked 11 0
Former/Current 0/0 4/7
Pack-years 11 0 11 52.2 ± 32
GOLD 0/1/2/3/4 11/0/0/0/0 0/3/8/0/0
FEV1/FVC, % 11 77.2 ± 5 11 60.4 ± 9*
FEV1, % predicted value 11 107.2 ± 10 11 73.2 ± 15*
VC, L 11 3.5 ± 1 11 3.6 ± 1
COPD chronic obstructive pulmonary disease, GOLD global initiative for chronic obstructive lung disease
*p < 0.001 compared with control
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concentration in plasma of GLY 50 μg and IND 150 μg
which were administered by inhalation once daily for
14 days were 216 pg/ml (0.5 nM) and 438.6 pg/ml (1.1
nM), respectively [28, 29]. However, there are no direct
evidence for lung concentration after inhalation, we de-
cided to select 10−8 M GLY and 10−9 M IND to access
the pharmacological interaction between GLY and IND.
Next, we investigated the effect of a combination of GLY
and IND on CCh- or TGF-β1-mediated gel contraction in
HFL1 cells. The combination of GLY 10−8 M and IND
10−9 M significantly suppressed CCh-augmented collagen
gel contraction (CCh; 67.0 ± 1.3% vs. CCh +GLY + IND;
76.0 ± 1.0%: P < 0.01) as well as TGF-β1-augmented gel
contraction (TGF-β1; 66.1 ± 1.1% vs. TGF-β1 +GLY +
IND; 71.2 ± 0.7%: P < 0.01) (Fig. 2e and g). The combin-
ation of 10−8 M GLY and 10−9 M IND significantly sup-
pressed CCh- or TGF-β1-induced α-SMA expression
(P < 0.01 and P < 0.05, respectively) (Fig. 2f and h).
Phenotypic differences in fibroblasts from non-smokers
and patients with COPD on CCh- or TGF -β1-induced
collagen gel contraction
We next examined the phenotypic features of fibroblasts
from non-smokers and patients with COPD in response
to CCh and TGF-β1 stimulation. CCh significantly aug-
mented collagen gel contraction mediated by the fibro-
blasts isolated from non-smokers (control; 82.0 ± 2.7%
vs. CCh; 80.0 ± 3.2%; P < 0.05) or patients with COPD
(control; 79.0 ± 2.8% vs. CCh; 73.0 ± 2.9%; P < 0.01)
(Fig. 3a). Similarly, TGF-β1 also augmented collagen gel
contraction mediated by the fibroblasts isolated from
non-smokers (control; 82.0 ± 2.7% vs. TGF-β1; 78.8 ±
2.7%; P < 0.01) or patients with COPD (control; 79.0 ±
2.8% vs. TGF-β1; 70.1 ± 4.0%, P < 0.01) (Fig. 3b). It is
noteworthy that the magnitudes of collagen gel contrac-
tion in response to CCh or TGF-β1 stimulation were
greater in the fibroblasts isolated from patients with
COPD than in those from non-smokers. Combination of
GLY 10−8 M and IND 10−9 M significantly suppressed
CCh- or TGF-β1-augmented collagen gel contraction in
the fibroblasts isolated from both non-smokers and
COPD subjects (P < 0.01) (Fig. 3c and d).
Effect of CCh on the release of endogenous TGF-β1
We assessed the effects of CCh on the release of en-
dogenous TGF-β1 and the effect of GLY and IND on the
release of endogenous TGF-β1 by fibroblasts. CCh stim-
ulated TGF-β1 release by HFL1 cells. The effect was sig-
nificantly suppressed by a combination of GLY 10−8 M
and IND 10−9 M (Fig. 4a). CCh-stimulated TGF-β1 release
was significantly higher in the primary lung fibroblasts
from patients with COPD than in those from non-
smokers (P < 0.05). The suppression of CCh-stimulated
TGF-β1 release by GLY 10−8 M plus IND 10−9 M was sig-
nificantly stronger in the fibroblasts isolated from patients
with COPD than in those from non-smokers (P < 0.05,
Fig. 4b).
This result suggested that CCh-induced collagen gel
contraction and α-SMA expression might be mediated
through a TGF-β1 autocrine release/paracrine mechanism.
Moreover, CCh-induced collagen gel contraction and
α-SMA expression were partially suppressed by SB431542,
a selective inhibitor of the TGF-β1 receptor, ALK5
(Fig. 4c and d).
Fig. 1 Effect of CCh, GLY or IND on collagen gel contraction and α-
SMA expression in HFL-1 cells. Cells were grown to sub-confluence
and deprived of serum for 24 h. Fibroblast-populated collagen gels
were released into serum-free DMEM and measured the gel size
daily by an image analyzer. a Gel size was measured in the pres-
ence of varying concentrations of CCh (b), GLY (e) or IND (f) on
day3. Vertical axis, gel size expressed as % of initial size; Horizontal
axis, conditions. All values represent the mean ± SEM in at least 3
separate experiments. HFL-1 cells were grown to sub-confluence in
monolayer culture and stimulated with CCh at the indicated times
or for 48 h at the indicated concentrations. After incubation, total
protein was extracted and western blot analysis was performed
with specific antibodies for α-SMA. Vertical axis: relative intensity of
α-SMA/β-actin ratio. Horizontal axis: time (c) and concentration of
CCh (d). All values represent the mean ± SEM in at least 3 separate
experiments. *P < 0.05, **P < 0.01 compared with control
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Quantification of acetylcholine release from lung
fibroblasts
Acetylcholine is mainly synthesized from choline and
acetyl-CoA by ChAT. Therefore, ChAT protein level in
HFL1 and A549 cells was semi-quantitatively assessed
by immunoblot. A549 cells were shown to release acetyl-
choline [30]. ChAT was detected in both HFL1 and
A549 cells. It was slightly, but significantly, stimulated
by TGF-β1 in HFL1 cells (Fig. 5a, P < 0.05). Interestingly,
ChAT protein was significantly higher in A549 cells
under basal conditions compared to that in HFL1 cells
and TGF-β1 did not alter ChAT protein level in A549
cells (Fig. 5a).
Next, we measured acetylcholine in the supernatants
of cultured fibroblasts by LC-MS/MS. Acetylcholine was
not detectable in the culture medium of HFL1 cells or
primary lung fibroblasts from non-smokers and patients
with COPD (Fig. 5b-d), although 2 × 10−9 M acetylcholine
could be detected as the positive control (Fig. 5e). Further-
more, TGF-β1 did not stimulate acetylcholine release in fi-
broblasts (Fig. 5b-d). This result indicated that the release
of acetylcholine from fibroblasts might be only a modest
level.
Effect of GLY and IND on CCh or TGF-β1 induced ERK5
phosphorylation
We explored the role of ERK5 in mediating CCh and
TGF-β1 signaling and the effect of GLY and IND on
ERK5 phosphorylation. CCh and TGF-β1 induced ERK5
phosphorylation (P < 0.05, Fig. 6a-d). GLY plus IND and
BIX02189, a specific MEK5-ERK5 inhibitor, significantly
suppressed CCh- or TGF-β1-induced ERK5 phosphoryl-
ation (P < 0.05, Fig. 6c and d). Moreover, CCh-induced
ERK5 phosphorylation was suppressed by SB431542
(Fig. 6c), suggesting that TGF-β1 autocrine release was
involved in CCh signaling. Notably, the basal level of
ERK5 expression was significantly higher in fibroblasts
from patients with COPD than in those from non-
smokers (P < 0.05, Fig. 6e), although ERK5 phosphoryl-
ation did not differ between the two groups (Fig. 6f ).
However, ERK5 phosphorylation in response to CCh
stimulation was higher in fibroblasts from patients
Fig. 2 Effect of GLY and/or IND on CCh- or TGF-β1-augmented gel contraction and α-SMA expression in HFL1 cells. Sub-confluent fibro-
blasts were placed in serum-free (SF)-DMEM for 24 h. Cells were pre-treated with GLY and IND for 30 min, casted into collagen gels, and
released into SF-DMEM containing various concentrations of GLY and/or IND with or without CCh (a, b, e) or TGF-β1 (c, d, g). Gel size
was measured on day 3. Vertical axis: gel size expressed as a percentage of control. Horizontal axis: conditions. All values represent the
mean ± SEM of three separate experiments, each performed in triplicate. For α-SMA assay, cells were grown to sub-confluence in mono-
layer culture and serum deprived for 24 h. Cells were then stimulated with CCh or TGF-β1 in the presence or absence of GLY and/or
IND. After 48 h of incubation with CCh and 24 h of incubation with TGF-β1, cells were harvested for immunoblotting using a α-SMA anti-
body (f, h). Vertical axis, relative intensity of α-SMA/β-actin ratio; Horizontal axis, conditions. Representative immunoblots are shown at the
top of each panel. All values represent the mean ± SEM in three different strains. †P < 0.05, † †P < 0.01, compared with solvent control.
*P < 0.05, **P < 0.01, compared with stimulus
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with COPD than in those from non-smokers (P < 0.05,
Fig. 6g). In contrast, in response to TGF-β1 stimula-
tion, ERK5 phosphorylation was similar in fibroblasts
from patients with COPD and non-smokers (Fig. 6h).
GLY plus IND significantly suppressed CCh- or TGF-
β1-induced ERK5 phosphorylation in fibroblasts re-
gardless of their origin (P < 0.05, Fig. 6g and h).
Fig. 3 CCh- or TGF-β1-augmented gel contraction was attenuated
by GLY and IND in primary lung fibroblasts. After 24 h of SF-DMEM
culture, lung fibroblasts from non-smokers or patients with COPD
were pre-treated with GLY or IND for 30 min, casted into collagen
gels and released into SF-DMEM in the presence or absence of CCh
(a), TGF-β1 (b), with or without GLY/IND (c, d). Gel size was measured
on day 3. Vertical axis: gel size expressed as a percentage of con-
trol. Horizontal axis: conditions. Each pair of symbols connected
by a line represents data of an individual cell strain isolated from
non-smokers or patients with COPD. Cells from non-smokers are
indicated by open circles, cells from patients with COPD (GOLD I) by
squares, and cells from patients with COPD (GOLD II) by closed cir-
cles. †P < 0.05, † † P < 0.01, compared with control. *P < 0.05, **P <
0.01, compared with stimulus. §P < 0.05, compared with non-
smokers and COPD lung fibroblasts in the same stimulus group
Fig. 4 Effect of CCh-mediated endogenous TGF-β1 release in lung
fibroblasts. Sub-confluent HFL1 cells (a) and primary lung fibroblasts (b)
were cultured in SF-DMEM for 24 h in the presence or absence of CCh
with or without GLY and/or IND. After 24 h of incubation, supernatants
were harvested and used for TGF-β1 quantification. Vertical axis:
TGF-β1 production expressed as amount per cells. Horizontal axis:
conditions. Each pair of symbols connected by a line represents
data of an individual cell strain isolated from non-smokers or patients
with COPD. Cells from non-smokers are indicated by open circles, cells
from patients with COPD (GOLD I) by squares, and cells from patients
with COPD (GOLD II) by closed circles. c Sub-confluent HFL1 cells were
cultured in SF-DMEM for 24 h. Cells were casted into collagen gels in
the presence of CCh with or without SB431542, a selective inhibitor of
the TGF-β1 receptor, ALK5. Gel size was measured on day 3. Vertical
axis: gel size expressed as a percentage of control. Horizontal axis:
conditions. All values represent the mean ± SEM of three separate
experiments, each performed in triplicate. d HFL1 cells were grown
to sub-confluence in monolayer culture and serum deprived for 24 h.
Cells were stimulated with CCh in the presence or absence of SB431542.
After 48 h of incubation, cells were harvested for the detection of α-SMA
by immunoblotting. Vertical axis, relative intensity of α-SMA/β-actin ratio;
Horizontal axis, conditions. All values represent the mean ± SEM of the
three different strains. †P< 0.05, compared with solvent control. *P< 0.05,
compared with stimulus. §P< 0.05, compared with non-smokers and
COPD lung fibroblasts in the same stimulus group
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Blockade of ERK5 phosphorylation resulted in the
suppression of collagen gel contraction and α-SMA
expression
We assessed whether ERK5 blockade altered CCh- or
TGF-β1-augmented collagen gel contraction and α-SMA
expression in fibroblasts. Pretreatment with BIX02189 or
Y-27632, a Rho kinase inhibitor, resulted in the significant
reduction of CCh- or TGF-β1-augmented collagen gel
contraction and α-SMA expression in HFL1 cells. How-
ever, PD98059, an ERK1/2 inhibitor did not significantly
attenuate CCh- or TGF-β1-augmented collagen gel
contraction and α-SMA expression (Fig. 7a and b).
CCh-augmented collagen gel contraction by fibroblasts
from patients with COPD or non-smokers was signifi-
cantly inhibited by BIX02189 (P < 0.01, Fig. 7c). However,
BIX02189 suppression of TGF-β1-augmented collagen gel
contraction was more significant in fibroblasts from
patients with COPD than in those from non-smokers
(P < 0.01 and P < 0.05, respectively) (Fig. 7d).
Discussion
In the current study, we demonstrated for the first time
that GLY and IND additively attenuated lung fibroblast-
mediated contraction of collagen gels in response to CCh
or TGF-β1. Interestingly, compared to lung fibroblasts iso-
lated from non-smokers, the response of lung fibroblasts
from patients with mild to moderate COPD to CCh- or
TGF-β1-induced collagen gel contraction as well as to
CCh-stimulated TGF-β1 release was higher. CCh or TGF-
β1 induced ERK5 phosphorylation and inhibition of ERK5
phosphorylation by GLY plus IND resulted in the re-
duction of CCh- or TGF-β1-augmented collagen gel
contraction and α-SMA expression in lung fibro-
blasts (Fig. 8). This functional involvement of a non-
neuronal cholinergic system provide new insights into
the pathogenesis of COPD and treatment strategy com-
bining inhaled IND and GLY to patients with develop-
ing airway fibrosis in early stage of COPD.
Accumulating evidence indicates that acetylcholine in
the airway may not only be released from parasympa-
thetic nerve, but also from bronchial epithelial [10] and
inflammatory cell [16] and may contribute in airway re-
modeling as a paracrine and autocrine mediator. Previ-
ous studies reported that normal lung fibroblasts express
muscarinic receptors and directly respond to cholinergic
stimulation, including proliferation and collagen synthe-
sis through ERK1/2 activation [12–14]. The cholinergic
agonist, relying on Rho kinase and autocrine TGF-β1 re-
lease, also induced fibroblast-to-myofibroblast transition
and α-SMA expression [15]. An in vivo study revealed
that anticholinergics inhibit lipopolysaccharide-induced
small airway fibrosis in guinea pigs [31].
Collagen gel contraction assay is an in vitro fibrosis
model developed to assess the regulation of contractile
Fig. 5 Determination of acetylcholine release by TGF-β1-stimulated
lung fibroblasts by using LC-MS/MS. HFL1 and A549 cells were grown
to sub-confluence in monolayer culture and serum deprived for 24 h.
Cells were stimulated with TGF-β1 and harvested for the detection of
ChAT by immunoblotting. Vertical axis, relative intensity of ChAT/β-
actin ratio; Horizontal axis, conditions. Representative immunoblots are
shown at the top of the panel. All values represent the mean ± SEM of
the three different strains (a). HFL1 cells (b) and primary lung fibroblast
from non-smokers (c) and patients with COPD (d) were grown to
sub-confluence and cultured in SF-DMEM with or without TGF-β1
for 24 h. Supernatants were then harvested into a 1.5 ml tube and
acetyl- and butyrylcholinesterase inhibitor (1 μM rivastigmine) was
added to prevent acetylcholine degradation before storing at− 80 °C
until assay. For the acetylcholine assay, the aliquots were thawed
immediately before analysis and 5 μl of the samples was injected
directly into the LC-MS/MS system. Data shown are representative
chromatograms (m/z 86.910–87.910), performed in each group (n = 3).
To obtain a standard report, acetylcholine was added to SF-DMEM. The
arrow indicates the peak of acetylcholine (e). Vertical axis, signal
intensity; Horizontal axis, retention time. *P < 0.05, **P < 0.01,
compared with control
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stress fiber, generally indicated as α-SMA, production
from activated myofibroblasts. When differentiated myo-
fibroblasts are cultured in such a collagen gel, the gels
are contracted by the traction force, suggesting the con-
tribution of fibrosis and abnormal tissue architecture
[32]. In this study, we demonstrated that the cholinergic
agent, CCh, augmented fibroblast-mediated collagen gel
contraction. Compared to lung fibroblasts from non-
smokers, parenchymal lung fibroblasts obtained from
patients with mild to moderate COPD showed higher
sensitivity to CCh or TGF-β1 in the collagen gel contrac-
tion assay. Moreover, fibroblasts obtained from patients
with COPD showed higher response to CCh stimulating
TGF-β1 release than those from non-smokers. These
findings suggest that acetylcholine and the subsequent
TGF-β1 autocrine loop play an important role in the
regulation of small airway fibrosis in patients with
COPD. A similar study reported that acetylcholine-
induced cell proliferation was enhanced in lung fibro-
blasts from patients with COPD compared to cells from
healthy non-smokers and healthy smokers, and muscar-
inic receptors were highly expressed in fibroblasts from
patients with COPD compared to that in fibroblasts
from controls [33]. However, we could not demonstrate
different expression levels of muscarinic receptors in
mild to moderate COPD fibroblasts compared to non-
smoker fibroblasts (data not shown), suggesting differ-
ent mechanisms of action.
ChAT, the synthase for acetylcholine, is expressed in
airway epithelial cells, airway smooth muscle cells, and fi-
broblasts as well as in inflammatory cells such as macro-
phages, lymphocytes, and granulocytes [16]. Furthermore,
epithelial and inflammatory cells release acetylcholine
[16], but that from the other cell types remains to be
Fig. 6 GLY and IND suppressed ERK5 phosphorylation in response to CCh or TGF-β1 in lung fibroblasts. Sub-confluent HFL1 cells were cultured
in SF-DMEM with or without CCh (a) or TGF-β1 (b) for the indicated times. ERK5 phosphorylation was determined by immunoblotting. The
bands with slower electrophoretic mobility corresponded to the activated kinase. Sub-confluent HFL1 cells (c, d) or primary fibroblasts (e-h)
were serum deprived for 24 h followed by stimulation with or without TGF-β1 or CCh in the presence or absence of GLY and/or IND,
SB431542 and ERK5 inhibitor (BIX02189) for 48 h. Cells were harvested and immunoblotted for ERK5. Each pair of symbols connected by a
line represents data from an individual cell strain. Cells from non-smokers are indicated by open circles, cells from patients with COPD
(GOLD I) by squares, and cells from patients with COPD (GOLD II) by closed circles. Vertical axis, the fold increase in activated kinase (p-
ERK5) against total ERK5 over control or relative intensity of ERK5/β-actin ratio; Horizontal axis, times or conditions. All values represent the mean
± SEM. †P < 0.05, compared with solvent control. *P < 0.05, **P < 0.01, compared with stimulus. §P < 0.05, compared with non-smokers and COPD lung
fibroblasts in the same stimulus group
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determined. Thus, we measured the level of acetylcholine
in the medium of cultured fibroblasts. However, acetyl-
choline was not detectable in the culture supernatant of fi-
broblasts from patients with COPD or non-smokers as
well as of HFL1 cells. GLY alone did not show any effect
on fibroblasts-mediated gel contraction and the cholin-
esterase inhibitor also could not potentiate collagen gel
contraction by fibroblasts (data not shown), indicating
that endogenous acetylcholine may not be involved in
this mechanism. Consistently, Profita et al. reported
that acetylcholine autocrine mechanism generated by
ChAT was not involved in lung fibroblast proliferation
[33]. In addition, ChAT expression and acetylcholine
release were identified from large airways, but not from
lung parenchyma, in ovalbumin-sensitized guinea pigs
[9]. These findings indicated that lung parenchymal fi-
broblasts do not synthesize detectable amounts of
acetylcholine although they do express ChAT.
ERK5, an atypical member of the MAPK family, plays
an important role in hypertrophic remodeling of cardio-
myocytes by enhancing cell viability and in chronic
glomerulonephritis by increasing ECM deposition [34].
BIX02189, a pharmacological inhibitor of MEK5/ERK5,
improved both lung fibrosis and survival rate in the
bleomycin-induced lung fibrosis model [17]. García-Hoz
et al. revealed that CCh induces the formation of Gαq/
Fig. 7 Inhibition of ERK5 resulted in the suppression of CCh- or TGF-β1-stimulated gel contraction and α-SMA expression in lung fibroblasts.
Sub-confluent HFL1 cells were pre-treated with ERK5 inhibitor (BIX02189), ERK1/2 inhibitor (PD98059), and Rho kinase inhibitor (Y27632) for
30 min followed by being casted into collagen gels and treated with CCh or TGF-β1. Gel size was measured on day 3. Vertical axis: gel size
expressed as a percentage of control. Horizontal axis: conditions. All values represent the mean ± SEM in three separate experiments, each
performed in triplicate (a). Sub-confluent HFL1 cells were serum deprived for 24 h followed by stimulation with CCh or TGF-β1 for 48 h. Cells
were then harvested for α-SMA immunoblotting. Vertical axis, relative intensity of α-SMA/β-actin ratio; Horizontal axis, conditions. All values
represent the mean ± SEM in the three different strains (b). Lung fibroblasts from non-smokers and subjects with COPD were grown to sub-confluence
and pre-treated with BIX02189 for 30 min followed by being casted into collagen gels and released into SF-DMEM with CCh (c) or TGF-β1 (d) in the
presence or absence of BIX02189. Gel size was measured on day 3. Vertical axis: gel size expressed as a percentage of control. Horizontal axis:
conditions. Each pair of symbols connected by a line represented data from an individual cell strain and the mean of three separate experiments. Cells
from non-smokers are indicated by open circles, cells from patients with COPD (GOLD I) by squares, and cells from patients with COPD (GOLD II) by
closed circles. †P < 0.05, ††P < 0.01, compared with solvent control. *P < 0.05, **P < 0.01, compared with stimulus. §P < 0.05, compared with non-smokers
and COPD lung fibroblasts in the same stimulus group
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protein kinase C (PKC) ζ and MEK5 protein complexes
to trigger ERK5 activation in mouse embryonic fibroblasts
[35]. Badshah et al. reported that TGF-β1 mediates ERK5
activation in human podocytes without the involvement of
the small GTPase Ras [36]. In the present study, CCh and
TGF-β1 induced ERK5 phosphorylation in lung fibro-
blasts, and BIX02189 attenuated CCh- or TGF-β1-
induced gel contraction and α-SMA expression. Further-
more, levels of basal ERK5 expression and CCh-induced
ERK5 phosphorylation were higher in fibroblasts obtained
from patients with COPD than in fibroblasts obtained
from non-smokers, suggesting that ERK5 signaling was in-
volved in developing airway fibrosis in COPD.
In clinical studies, inhalation of a combination of GLY
and IND showed additive effects in terms of FEV1 be-
tween 5 min and 3 h post-inhalation in patients with
moderate-to-sever COPD, with a synergistic effect at
15 min post-inhalation compared to the administration
of either drug alone [37]. Previous studies using isolated
human airway demonstrated that aclidinium and formo-
terol showed synergistic inhibition of airway smooth
muscle tone induced by acetylcholine from 0 to 6 h
when administered at low concentrations [38]. In the
current study, we report for the first time that the GLY
and IND combination has an additive inhibitory effect
on fibroblast-mediated gel contraction in response to
CCh or TGF-β1. We set the concentrations of GLY and
IND in this experiment using plasma pharmacokinetics
from a clinical trial; however, the actual concentration of
these compounds in the airway is unclear. To verify the
desired effectiveness and safety of GLY, IND, and
BIX02189 in preventing airway fibrosis for clinical use,
computational simulation techniques, such as fluidic dy-
namics, are needed to calculate the drug concentration
in the peripheral airway [39].
Conclusion
Our results demonstrate that GLY and IND combination
inhibits lung fibroblast-mediated collagen gel contraction
and α-SMA expression in response to CCh or TGF-β1.
CCh induced TGF-β1 self-sustaining signaling loops by po-
tentiating ERK5 signaling, which was suppressed by GLY
and IND. Notably, the magnitudes of CCh- and TGF-β1-
induced fibrotic activities were greater in fibroblasts iso-
lated from mild to moderate COPD subjects than in those
from non-smokers, suggesting the substantial roles of
CCh- and TGF-β1 in pathogenesis of airway fibrosis. Al-
though the present study was performed under controlled
experimental settings, ERK5 might be a novel therapeutic
target for airway fibrosis and the inhaled GLY and IND
combination therapy may be useful for early intervention
to prevent the development of airway fibrosis in COPD.
Abbreviations
ALK5: Activin receptor–like kinase 5; CCh: Carbachol; ChAT: Choline-
acetyltransferase; COPD: Chronic obstructive pulmonary disease;
ELISA: Enzyme-linked immunosorbent assay; ERK1/2: Extracellular signal-
regulated kinase 1/2; ERK5: Extracellular-signal-regulated kinase 5;
FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity;
GLY: Glycopyrronium; IND: Indacaterol; LABA: Long-acting β2 adrenergic
Fig. 8 Schematic illustration of CCh-induced endogenous TGF-β1 signaling loop in COPD lung fibroblasts. Carbachol (CCh) induces ERK5 activation
directly or indirectly through stimulating endogenous transforming growth factor-β1 (TGF-β1) release. Glycopyrronium (GLY) directly blocks
CCh binding to its receptor, while indacaterol (IND) interrupts CCh signaling pathway or TGF-β1-induced ERK5 activation. Through these
mechanisms, GLY plus IND blocked CCh- or TGF-β1-augmented collagen gel contraction and α-SMA expression
Namba et al. Respiratory Research  (2017) 18:46 Page 11 of 13
receptor agonist; LAMA: Long-acting muscarinic receptor antagonist; LC-MS/
MS: Liquid chromatography tandem-mass spectrometry; MAPK: Mitogen-
activated protein kinase; TGF-β1: Transforming growth factor-β1; α-SMA: α-
smooth muscle actin
Acknowledgements
We thank I. Taki, L. Ning, N. Okamoto, T. Ito, R. Mineki, and E. Kobayashi for
excellent assistance and advice.
Funding
This study was supported by Novartis Pharma K.K. Provision of glycopyrronium
and indacaterol from Novartis Pharma AG.
Availability of data and materials
Not applicable.
Authors’ contributions
Conception and design: YN, ST, XL, KT; Acquisition of data: MT, KK, KYN, HT,
NK, AO; Analysis and interpretation of data: YN, ST, AO, XL, KT; Drafting the
manuscript for important intellectual content: YN, ST, MT, KK, KYN, HT, NK;
Revising the manuscript for important intellectual content: YN, ST, AO, XL, KT;
Final approval of the manuscript: YN, ST, MT, KK, KYN, HT, NK, AO, XL, KT.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Institutional Review Board at the Juntendo University School of Medicine
approved the procedures. All patients provided written, informed consent
(No. 2013051).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Respiratory Medicine, Juntendo University Faculty of Medicine &
Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421,
Japan. 2Research Institute for Diseases of Old Ages, Juntendo University
Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421,
Japan. 3Laboratory of Proteomics and Biomolecular Science, Research
Support Center, Juntendo University Graduate School of Medicine, 2-1-1
Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. 4Departments of Pathology and
Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku,
Tokyo 113-8421, Japan. 5Pulmonary Critical Care and Sleep Medicine,
University of Nebraska Medical Center, Omaha, NE, USA.
Received: 15 December 2016 Accepted: 6 March 2017
References
1. Berankova K, Uhlik J, Honkova L, Pohunek P. Structural changes in the
bronchial mucosa of young children at risk of developing asthma. Pediatr
Allergy Immunol. 2014;25:136–42.
2. Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, Boriek AM,
Casaburi R, Criner GJ, Diaz AA, et al. Association Between Functional Small
Airways Disease and FEV Decline in COPD. Am J Respir Crit Care Med. 2016.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM,
Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway
obstruction in chronic obstructive pulmonary disease. N Engl J Med.
2004;350:2645–53.
4. Rennard SI, Wachenfeldt K. Rationale and emerging approaches for
targeting lung repair and regeneration in the treatment of chronic
obstructive pulmonary disease. Proc Am Thorac Soc. 2011;8:368–75.
5. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y,
Yamasawa F, Nakahara K, Umeda A. Increased expression of transforming
growth factor-beta1 in small airway epithelium from tobacco smokers and
patients with chronic obstructive pulmonary disease (COPD). Am J Respir
Crit Care Med. 2001;163:1476–83.
6. Gohy ST, Detry BR, Lecocq M, Bouzin C, Weynand BA, Amatngalim GD,
Sibille YM, Pilette C. Polymeric immunoglobulin receptor down-regulation
in chronic obstructive pulmonary disease. Persistence in the cultured
epithelium and role of transforming growth factor-beta. Am J Respir Crit
Care Med. 2014;190:509–21.
7. Kistemaker LE, Oenema TA, Meurs H, Gosens R. Regulation of airway
inflammation and remodeling by muscarinic receptors: perspectives on
anticholinergic therapy in asthma and COPD. Life Sci. 2012;91:1126–33.
8. Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, Davies DE,
Howarth PH. Effect of bronchoconstriction on airway remodeling in asthma.
N Engl J Med. 2011;364:2006–15.
9. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal
cholinergic system in humans: expression, function and pathophysiology.
Life Sci. 2003;72:2055–61.
10. Klapproth H, Reinheimer T, Metzen J, Munch M, Bittinger F, Kirkpatrick CJ,
Hohle KD, Schemann M, Racke K, Wessler I. Non-neuronal acetylcholine, a
signalling molecule synthezised by surface cells of rat and man. Naunyn
Schmiedebergs Arch Pharmacol. 1997;355:515–23.
11. Kummer W, Wiegand S, Akinci S, Schinkel AH, Wess J, Koepsell H,
Haberberger RV, Lips KS. Role of acetylcholine and muscarinic receptors
in serotonin-induced bronchoconstriction in the mouse. J Mol Neurosci.
2006;30:67–8.
12. Matthiesen S, Bahulayan A, Holz O, Racke K. MAPK pathway mediates muscarinic
receptor-induced human lung fibroblast proliferation. Life Sci. 2007;80:2259–62.
13. Matthiesen S, Bahulayan A, Kempkens S, Haag S, Fuhrmann M, Stichnote C,
Juergens UR, Racke K. Muscarinic receptors mediate stimulation of human
lung fibroblast proliferation. Am J Respir Cell Mol Biol. 2006;35:621–7.
14. Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate
stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J.
2008;32:555–62.
15. Milara J, Serrano A, Peiro T, Gavalda A, Miralpeix M, Morcillo EJ, Cortijo J.
Aclidinium inhibits human lung fibroblast to myofibroblast transition. Thorax.
2012;67:229–37.
16. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal
cholinergic system in humans. Br J Pharmacol. 2008;154:1558–71.
17. Kim S, Lim JH, Woo CH. ERK5 inhibition ameliorates pulmonary fibrosis via
regulating Smad3 acetylation. Am J Pathol. 2013;183:1758–68.
18. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J,
Celli BR, Chen R, Decramer M, Fabbri LM, et al.: Global Strategy for the
Diagnosis, Management, and Prevention of Chronic Obstructive Lung
Disease 2017 Report. Respirology 2017.
19. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R,
Seibold W, Moroni-Zentgraf P, Bateman ED. Tiotropium in asthma poorly
controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207.
20. Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H,
Banerji D. Safety and efficacy of dual bronchodilation with QVA149 in COPD
patients: the ENLIGHTEN study. Respir Med. 2013;107:1558–67.
21. Holz O, Zuhlke I, Jaksztat E, Muller KC, Welker L, Nakashima M, Diemel KD,
Branscheid D, Magnussen H, Jorres RA. Lung fibroblasts from patients with
emphysema show a reduced proliferation rate in culture. Eur Respir J.
2004;24:575–9.
22. Elsdale T, Bard J. Collagen substrata for studies on cell behavior. J Cell Biol.
1972;54:626–37.
23. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by
contraction of collagen lattices by human fibroblasts of different
proliferative potential in vitro. Proc Natl Acad Sci U S A. 1979;76:1274–8.
24. Xu BE, Stippec S, Lenertz L, Lee BH, Zhang W, Lee YK, Cobb MH. WNK1 activates
ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem. 2004;279:7826–31.
25. Reinheimer T, Bernedo P, Klapproth H, Oelert H, Zeiske B, Racke K, Wessler I.
Acetylcholine in isolated airways of rat, guinea pig, and human: species
differences in role of airway mucosa. Am J Physiol. 1996;270:L722–728.
26. Liu X, Wen FQ, Kobayashi T, Abe S, Fang Q, Piek E, Bottinger EP, Roberts AB,
Rennard SI. Smad3 mediates the TGF-beta-induced contraction of type I
collagen gels by mouse embryo fibroblasts. Cell Motil Cytoskeleton.
2003;54:248–53.
27. Kobayashi T, Liu X, Wen FQ, Kohyama T, Shen L, Wang XQ, Hashimoto M,
Mao L, Togo S, Kawasaki S, et al. Smad3 mediates TGF-beta1-induced
collagen gel contraction by human lung fibroblasts. Biochem Biophys Res
Commun. 2006;339:290–5.
Namba et al. Respiratory Research  (2017) 18:46 Page 12 of 13
28. Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the
pharmacokinetics of glycopyrronium in the lung using a population
pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76:868–79.
29. Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF. Cardiac
safety of indacaterol in healthy subjects: a randomized, multidose, placebo-
and positive-controlled, parallel-group thorough QT study. BMC Pulm Med.
2011;11:31.
30. Xu ZP, Devillier P, Xu GN, Qi H, Zhu L, Zhou W, Hou LN, Tang YB, Yang K,
Yu ZH, et al. TNF-alpha-induced CXCL8 production by A549 cells: involvement
of the non-neuronal cholinergic system. Pharmacol Res. 2013;68:16–23.
31. Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, Maarsingh H,
Zaagsma J, Meurs H. Tiotropium inhibits pulmonary inflammation and
remodelling in a guinea pig model of COPD. Eur Respir J. 2011;38:789–96.
32. Mio T, Liu X, Toews ML, Adachi Y, Romberger DJ, Spurzem JR, Rennard SI.
Bradykinin augments fibroblast-mediated contraction of released collagen
gels. Am J Physiol Lung Cell Mol Physiol. 2001;281:L164–171.
33. Profita M, Bonanno A, Siena L, Bruno A, Ferraro M, Montalbano AM, Albano GD,
Riccobono L, Casarosa P, Pieper MP, Gjomarkaj M. Smoke, choline
acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic
obstructive pulmonary disease. J Pharmacol Exp Ther. 2009;329:753–63.
34. Urushihara M, Takamatsu M, Shimizu M, Kondo S, Kinoshita Y, Suga K,
Kitamura A, Matsuura S, Yoshizumi M, Tamaki T, et al. ERK5 activation
enhances mesangial cell viability and collagen matrix accumulation in rat
progressive glomerulonephritis. Am J Physiol Renal Physiol. 2010;298:F167–176.
35. Garcia-Hoz C, Sanchez-Fernandez G, Diaz-Meco MT, Moscat J, Mayor F, Ribas C.
G alpha(q) acts as an adaptor protein in protein kinase C zeta (PKCzeta)-
mediated ERK5 activation by G protein-coupled receptors (GPCR). J Biol Chem.
2010;285:13480–9.
36. Badshah II, Baines DL, Dockrell ME. Erk5 is a mediator to TGFbeta1-induced
loss of phenotype and function in human podocytes. Front Pharmacol.
2014;5:71.
37. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG.
Translational Study Searching for Synergy between Glycopyrronium and
Indacaterol. COPD. 2015;12:175–81.
38. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavalda A, Matera MG.
Pharmacological characterization of the interaction between aclidinium
bromide and formoterol fumarate on human isolated bronchi. Eur J
Pharmacol. 2014;745:135–43.
39. Ravi Kannan R, Przekwas AJ, Singh N, Delvadia R, Tian G, Walenga R.
Pharmaceutical aerosols deposition patterns from a Dry Powder Inhaler:
Euler Lagrangian prediction and validation. Med Eng Phys. 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Namba et al. Respiratory Research  (2017) 18:46 Page 13 of 13
